Tsuzuki, S., Nakanishi, S., Tamaki, M., Oshiro, T., Miki, J., Yamada, H., . . . Egawa, S. (2021). Initial dose reduction of enzalutamide does not decrease the incidence of adverse events in castration-resistant prostate cancer. Public Library of Science (PLoS).
Chicago Style (17th ed.) CitationTsuzuki, Shunsuke, et al. Initial Dose Reduction of Enzalutamide Does Not Decrease the Incidence of Adverse Events in Castration-resistant Prostate Cancer. Public Library of Science (PLoS), 2021.
MLA (8th ed.) CitationTsuzuki, Shunsuke, et al. Initial Dose Reduction of Enzalutamide Does Not Decrease the Incidence of Adverse Events in Castration-resistant Prostate Cancer. Public Library of Science (PLoS), 2021.
Warning: These citations may not always be 100% accurate.